658 results on '"Bonig, Halvard"'
Search Results
202. Enumeration of viable CD34+ cells by flow cytometry in blood, bone marrow and cord blood: results of a study of the novel BD™ stem cell enumeration kit
- Author
-
Dauber, Katrin, primary, Becker, Daniela, additional, Odendahl, Marcus, additional, Seifried, Erhard, additional, Bonig, Halvard, additional, and Tonn, Torsten, additional
- Published
- 2011
- Full Text
- View/download PDF
203. Automatic interface-controlled apheresis collection of stem/progenitor cells: results from an autologous donor validation trial of a novel stem cell apheresis device
- Author
-
Reinhardt, Peter, primary, Brauninger, Susanne, additional, Bialleck, Heike, additional, Thorausch, Kristin, additional, Smith, Richard, additional, Schrezenmeier, Hubert, additional, Seifried, Erhard, additional, Wiesneth, Markus, additional, and Bonig, Halvard, additional
- Published
- 2010
- Full Text
- View/download PDF
204. Adjuvant CD49d Blockade Eradicates Chemoresistant ALL
- Author
-
Hsieh, Yao-Te, primary, Park, Eugene, additional, Jiang, Enzi, additional, Dauber, Katrin, additional, Chudziak, Doreen, additional, Schaefer, Paul, additional, Klemm, Lars, additional, Scharman, Carlton, additional, Kang, Eun-Suk, additional, Koo, Hong-Hoe, additional, Loh, Mignon L., additional, Hofmann, Wolf Karsten, additional, Heisterkamp, Nora, additional, Muschen, Markus, additional, Shimada, Hiroyuki, additional, Bonig, Halvard, additional, and Kim, Yong-Mi, additional
- Published
- 2010
- Full Text
- View/download PDF
205. Vagrant Stem Cells Draft Their Gene Companions
- Author
-
Bonig, Halvard, primary and Papayannopoulou, Thalia, additional
- Published
- 2010
- Full Text
- View/download PDF
206. Preclinical Evaluation of Tysabri as a Novel Adjuvant Therapy against Drug Resistant B-ALL.
- Author
-
Hsieh, Yao-Te, primary, Jiang, Enzi, additional, Scharman, Carlton, additional, Waters, Ella, additional, Park, Eugene, additional, Kadavallore, Asha, additional, Bonig, Halvard, additional, and Kim, Yong-Mi, additional
- Published
- 2009
- Full Text
- View/download PDF
207. On the adaptation of endosteal stem cell niche function in response to stress
- Author
-
Jiang, Yi, primary, Bonig, Halvard, additional, Ulyanova, Tatiana, additional, Chang, KaiHsin, additional, and Papayannopoulou, Thalia, additional
- Published
- 2009
- Full Text
- View/download PDF
208. Blockade of α6-Integrin Reveals Diversity in Homing Patterns Among Human, Baboon, and Murine Cells
- Author
-
Bonig, Halvard, primary, Priestley, Gregory V., additional, Wohlfahrt, Martin, additional, Kiem, Hans-Peter, additional, and Papayannopoulou, Thalia, additional
- Published
- 2009
- Full Text
- View/download PDF
209. Insights into the biology of mobilized hematopoietic stem/progenitor cells through innovative treatment schedules of the CXCR4 antagonist AMD3100
- Author
-
Bonig, Halvard, primary, Chudziak, Doreen, additional, Priestley, Greg, additional, and Papayannopoulou, Thalia, additional
- Published
- 2009
- Full Text
- View/download PDF
210. Concurrent Blockade of α4-Integrin and CXCR4 in Hematopoietic Stem/Progenitor Cell Mobilization
- Author
-
Bonig, Halvard, primary, Watts, Korashon L., additional, Chang, Kai-Hsin, additional, Kiem, Hans-Peter, additional, and Papayannopoulou, Thalia, additional
- Published
- 2009
- Full Text
- View/download PDF
211. Oral Small Molecule Inhibitor of VLA-4 Overcomes Adhesion Mediated Chemotherapy Resistance of Acute Myeloid Leukemia (AML) Blasts in Vitro, without Impairment of Normal Blood Cell Recovery When Combined with Chemotherapy in Vivo
- Author
-
Becker, Pamela s., primary, Appelbaum, Frederick R., additional, Chien, Sylvia, additional, Zhao, Xin, additional, Bonig, Halvard, additional, Mukasa, Ryuta, additional, and Papayannopoulou, Thalia, additional
- Published
- 2008
- Full Text
- View/download PDF
212. Response: More about multiple sclerosis, natalizumab, and CD34+ hematopoietic progenitors
- Author
-
Bonig, Halvard, primary, Wundes, Annette, additional, and Papayannopoulou, Thalia, additional
- Published
- 2008
- Full Text
- View/download PDF
213. Insights into the Biology of Mobilized Cells through Innovative Treatment Schedules of the CXCR4 Antagonist AMD3100.
- Author
-
Bonig, Halvard, primary and Papayannopoulou, Thalia, primary
- Published
- 2007
- Full Text
- View/download PDF
214. Hematopoietic Stem/Progenitor Cells (HSPC) Mobilization Parameters in Patients Chronically Treated with the CD49d Blocking Antibody Natalizumab.
- Author
-
Bonig, Halvard, primary, Wundes, Annette, primary, Chang, Kai-Hsin, primary, Lucas, Sylvia, primary, and Papayannopoulou, Thalia, primary
- Published
- 2007
- Full Text
- View/download PDF
215. Hematopoietic Progenitor Cells (HPC) from Mobilized Peripheral Blood Display Enhanced Migration and Marrow Homing Compared to Steady-State Bone Marrow HPC
- Author
-
Bonig, Halvard, primary, Priestley, Gregory V., additional, Oehler, Vivian, additional, and Papayannopoulou, Thalia, additional
- Published
- 2007
- Full Text
- View/download PDF
216. A validation protocol and evaluation algorithms to determine compatibility of cell therapy product matrices in microbiological testing.
- Author
-
Klarmann, Dieter, Sireis, Walid, Hogardt, Michael, Kempf, Volkhard, Seifried, Erhard, and Bonig, Halvard
- Published
- 2015
- Full Text
- View/download PDF
217. Concise Review: CXCR4/CXCL12 Signaling in Immature Hematopoiesis-Lessons From Pharmacological and Genetic Models.
- Author
-
Bonig, Halvard and Karpova, Darja
- Subjects
HEMATOPOIETIC stem cells ,MESENCHYMAL stem cells ,CHEMOKINE receptors - Abstract
Dominant, although nonexclusive roles of CXCR4 and its chief ligand CXCL12 in bone marrow (BM) retention and preservation of the relative quiescence of hematopoietic stem/progenitor cells (HSPCs), along with their involvement in human immunodeficiency virus infection, in trafficking of mature hematopoietic cells to sites of inflammation and in orderly migration of nonhematopoietic cells during embryogenesis, explain the significant interest of the scientific community in the mode of action of this receptor-ligand pair. In this focused review, we seek to distil from the large body of information that has become available over the years some of the key findings about the role of CXCR4/CXCL12 in normal immature hematopoiesis. It is hoped that understanding the mechanistic insights gained there from will help generate hypotheses about potential avenues in which cancer/leukemia cell behavior can be modified by interference with this pathway. S tem C ells 2015;33:2391-2399 [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
218. Red blood cell depletion from bone marrow and peripheral blood buffy coat: a comparison of two new and three established technologies.
- Author
-
Sorg, Nadine, Poppe, Carolin, Bunos, Milica, Wingenfeld, Eva, Hümmer, Christiane, Krämer, Ariane, Stock, Belinda, Seifried, Erhard, and Bonig, Halvard
- Subjects
BONE marrow transplantation ,BUFFY coat ,ERYTHROCYTES ,ABO blood group system ,DENSITY gradient centrifugation ,CD34 antigen - Abstract
BACKGROUND Red blood cell (RBC) depletion is a standard technique for preparation of ABO-incompatible bone marrow transplants (BMTs). Density centrifugation or apheresis are used successfully at clinical scale. The advent of a bone marrow (BM) processing module for the Spectra Optia (Terumo BCT) provided the initiative to formally compare our standard technology, the COBE2991 (Ficoll, manual, 'C') with the Spectra Optia BMP (apheresis, semiautomatic, 'O'), the Sepax II NeatCell (Ficoll, automatic, 'S'), the Miltenyi CliniMACS Prodigy density gradient separation system (Ficoll, automatic, 'P'), and manual Ficoll ('M'). C and O handle larger product volumes than S, P, and M. STUDY DESIGN AND METHODS Technologies were assessed for RBC depletion, target cell (mononuclear cells [MNCs] for buffy coats [BCs], CD34+ cells for BM) recovery, and cost/labor. BC pools were simultaneously purged with C, O, S, and P; five to 18 BM samples were sequentially processed with C, O, S, and M. RESULTS Mean RBC removal with C was 97% (BCs) or 92% (BM). From both products, O removed 97%, and P, S, and M removed 99% of RBCs. MNC recovery from BC (98% C, 97% O, 65% P, 74% S) or CD34+ cell recovery from BM (92% C, 90% O, 67% S, 70% M) were best with C and O. Polymorphonuclear cells (PMNs) were depleted from BCs by P, S, and C, while O recovered 50% of PMNs. Time savings compared to C or M for all tested technologies are considerable. CONCLUSION All methods are in principle suitable and can be selected based on sample volume, available technology, and desired product specifications beyond RBC depletion and MNC and/or CD34+ cell recovery. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
219. Characterization of Bone Marrow Mononuclear Cells on Biomaterials for Bone Tissue Engineering In Vitro.
- Author
-
Henrich, Dirk, Verboket, René, Schaible, Alexander, Kontradowitz, Kerstin, Oppermann, Elsie, Brune, Jan C., Nau, Christoph, Meier, Simon, Bonig, Halvard, Marzi, Ingo, and Seebach, Caroline
- Subjects
BIOMEDICAL engineering ,BIOMEDICAL materials ,BONE marrow ,BONES ,RESEARCH funding ,SCANNING electron microscopy ,STATISTICS ,STEM cells ,DATA analysis ,DESCRIPTIVE statistics ,IN vitro studies ,KRUSKAL-Wallis Test - Abstract
Bone marrow mononuclear cells (BMCs) are suitable for bone tissue engineering. Comparative data regarding the needs of BMC for the adhesion on biomaterials and biocompatibility to various biomaterials are lacking to a large extent. Therefore, we evaluated whether a surface coating would enhance BMC adhesion and analyze the biocompatibility of three different kinds of biomaterials. BMCs were purified from human bone marrow aspirate samples. Beta tricalcium phosphate (β-TCP, without coating or coated with fibronectin or human plasma), demineralized bone matrix (DBM), and bovine cancellous bone (BS) were assessed. Seeding efficacy on β-TCP was 95% regardless of the surface coating. BMC demonstrated a significantly increased initial adhesion on DBM and β-TCP compared to BS. On day 14, metabolic activity was significantly increased in BMC seeded on DBM in comparison to BMC seeded on BS. Likewise increased VEGF-synthesis was observed on day 2 in BMC seeded on DBM when compared to BMC seeded on BS. The seeding efficacy of BMC on uncoated biomaterials is generally high although there are differences between these biomaterials. Beta-TCP and DBM were similar and both superior to BS, suggesting either as suitable materials for spatial restriction of BMC used for regenerative medicine purposes in vivo. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
220. Biosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?
- Author
-
Bonig, Halvard, Becker, Petra S, Schwebig, Arnd, and Turner, Matthew
- Abstract
Biosimilars are approved biologics with comparable quality, safety, and efficacy to a reference product. Unlike generics, which are chemically manufactured copies of small-molecule drugs with relatively simple chemical structures, the biosimilar designation is applied to drugs that are produced by living organisms, implying much more difficult to control manufacturing and purification procedures. To account for these complexities, the European Medicines Agency (EMA), the US Food and Drug Administration, the Australian Therapeutic Goods Administration, and other regulatory authorities have devised and implemented specific, markedly more demanding pathways for the evaluation and approval of biosimilars. To date, several biosimilars have been approved, including versions of somatropin, erythropoietin, and granulocyte-colony-stimulating factor (G-CSF), and several biosimilar monoclonal antibodies are currently in development. The reference G-CSF product (Neupogen, Amgen) has been used for many years for prevention and treatment of neutropenia and also for mobilization of peripheral blood stem cells (PBSCs). However, concerns have been raised about the safety and efficacy of biosimilar G-CSF during PBSC mobilization procedures, especially in healthy donors. This article reviews the available evidence on the use of biosimilar G-CSF in this setting. Aggregate clinical evidence supports the assessment by the EMA of biosimilar and originator G-CSF as highly biologically similar, with respect to desired and undesired effects. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
221. The p67 laminin receptor identifies human erythroid progenitor and precursor cells and is functionally important for their bone marrow lodgment
- Author
-
Bonig, Halvard, primary, Chang, Kai-Hsin, additional, Nakamoto, Betty, additional, and Papayannopoulou, Thalia, additional
- Published
- 2006
- Full Text
- View/download PDF
222. Long-term functional impairment of hemopoietic progenitor cells engineered to express the S1 catalytic subunit of pertussis toxin
- Author
-
Bonig, Halvard, primary, Rohmer, Laurence, additional, and Papayannopoulou, Thalia, additional
- Published
- 2005
- Full Text
- View/download PDF
223. Gi Protein Signals Are Required for BM Homing of Hemopoietic Progenitor Cells, and Cooperate with Alpha4-Intergrin and Endothelial Selectins.
- Author
-
Bonig, Halvard, primary, Priestley, Greg V., additional, Jiang, Yi, additional, and Papayannopoulou, Thalia, additional
- Published
- 2004
- Full Text
- View/download PDF
224. Co-culture of primary human T cells with leukemia cells to measure regulatory T cell expansion
- Author
-
Külp, Marius, Diehl, Laura, Bonig, Halvard, and Marschalek, Rolf
- Abstract
The expansion of regulatory T cells (Tregs) is known to be mediated by cytokines including IL-10 and TGFβ but has additionally been shown to depend on the interaction of the immune receptors ICOSLG and ICOS. Here, we describe a co-culture system which enables quantification of the ability of leukemia cells to induce Treg expansion through secreted cytokines and direct receptor interactions. The protocol is applicable for MHC-matched and -unmatched experiments and allows assessment of Treg expansion without using a mouse model.
- Published
- 2022
- Full Text
- View/download PDF
225. RUNX1 represses the erythroid gene expression program during megakaryocytic differentiation
- Author
-
Kuvardina, Olga N., Herglotz, Julia, Kolodziej, Stephan, Kohrs, Nicole, Herkt, Stefanie, Wojcik, Bartosch, Oellerich, Thomas, Corso, Jasmin, Behrens, Kira, Kumar, Ashok, Hussong, Helge, Urlaub, Henning, Koch, Joachim, Serve, Hubert, Bonig, Halvard, Stocking, Carol, Rieger, Michael A., and Lausen, Jörn
- Abstract
The activity of antagonizing transcription factors represents a mechanistic paradigm of bidirectional lineage–fate control during hematopoiesis. At the megakaryocytic/erythroid bifurcation, the crossantagonism of krueppel-like factor 1 (KLF1) and friend leukemia integration 1 (FLI1) has such a decisive role. However, how this antagonism is resolved during lineage specification is poorly understood. We found that runt-related transcription factor 1 (RUNX1) inhibits erythroid differentiation of murine megakaryocytic/erythroid progenitors and primary human CD34+progenitor cells. We show that RUNX1 represses the erythroid gene expression program during megakaryocytic differentiation by epigenetic repression of the erythroid master regulator KLF1. RUNX1 binding to the KLF1locus is increased during megakaryocytic differentiation and counterbalances the activating role of T-cell acute lymphocytic leukemia 1 (TAL1). We found that corepressor recruitment by RUNX1 contributes to a block of the KLF1-dependent erythroid gene expression program. Our data indicate that the repressive function of RUNX1 influences the balance between erythroid and megakaryocytic differentiation by shifting the balance between KLF1 and FLI1 in the direction of FLI1. Taken together, we show that RUNX1 is a key player within a network of transcription factors that represses the erythroid gene expression program.
- Published
- 2015
- Full Text
- View/download PDF
226. Epigenetic Modifications and Chromosome Conformations of the Beta Globin Locus throughout Development.
- Author
-
Chang, Kai-Hsin, Fang, Xiangdong, Wang, Hao, Huang, Andy, Cao, Hua, Yang, Yadong, Bonig, Halvard, Stamatoyannopoulos, John, and Papayannopoulou, Thalia
- Subjects
CHROMOSOME abnormalities ,BETA globin ,HUMAN embryos ,STEM cells ,GENETIC regulation ,GENE expression ,CELL lines ,CELL growth - Abstract
Human embryonic stem cells provide an alternative to using human embryos for studying developmentally regulated gene expression. The co-expression of high levels of embryonic ε and fetal γ globin by the hESC-derived erythroblasts allows the interrogation of ε globin regulation at the transcriptional and epigenetic level which could only be attained previously by studying cell lines or transgenic mice. In this study, we compared the histone modifications across the β globin locus of the undifferentiated hESCs and hESC-, FL-, and mobilized PB CD34 cells-derived erythroblasts, which have distinct globin expression patterns corresponding to their developmental stages. We demonstrated that the histone codes employed by the β globin locus are conserved throughout development. Furthermore, in spite of the close proximity of the ε globin promoter, as compared to the β or γ globin promoter, with the LCR, a chromatin loop was also formed between the LCR and the active ε globin promoter, similar to the loop that forms between the β or γ globin promoters and the LCR, in contrary to the previously proposed tracking mechanism. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
227. Enumeration of viable CD34++ cells by flow cytometry in blood, bone marrow and cord blood: results of a study of the novel BD™™ stem cell enumeration kit.
- Author
-
Dauber, Katrin, Becker, Daniela, Odendahl, Marcus, Seifried, Erhard, Bonig, Halvard, and Tonn, Torsten
- Subjects
STEM cell transplantation research ,FLOW cytometry ,LEUCOCYTES ,TRANSPLANTATION immunology ,TRANSPLANTATION of cell nuclei ,TRANSPLANTATION of organs, tissues, etc. ,CYTOLOGICAL techniques - Abstract
Background aims. Enumeration of CD34
++ cells in leukocyte-rich cell suspensions is important for clinical decision-making in stem cell transplantation. Single-platform flow cytometry assays offer the significant advantages of speed and reproducibility, and have therefore become the gold standard in stem cell enumeration. The clinical community has recently defined the need for stem cell enumeration kits that incorporate viability dyes. The purpose of this study was to evaluate a novel assay, BD Biosciences'' (BD) stem cell enumeration kit (SCE kit‡‡ ), in relation to Beckman Coulter's (BC) commercially available BC Stem-Kit™™. Methods. Fresh/freeze-thawed samples from leukapheresis, bone marrow and cord blood, and fresh normal/mobilized blood, were analyzed with both assays (simultaneous detection of side/forward scatter and three fluorescence signals) on two flow cytometry platforms, BD FACSCanto II and BD FACSCalibur. Results. Results from both assays were highly congruent, with an overall r2 ≥≥ 0.99 (all specimen types included), a linear correlation across all CD34++ cell frequencies and concentrations, and an almost ideal steepness of the trend line. Conclusions. Both assays functioned reliably. Being based on single-platform International Society of Hematotherapy and Graft Engineering (ISHAGE) guidelines and similar staining methods, both assays essentially come to identical results. For most specimen types, the viability of CD34++ cells was equal to overall leukocyte viability. In summary, in the hands of an experienced technician, the BD™™ SCE kit and the BC Stem-Kit are equivalent. The infrequent user might derive benefit from the fact that counting spheres are pre-pipetted into the Trucount tube for the SCE kit, making this assay less susceptible to pipetting inaccuracy. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
228. Retained functional normal and preleukemic HSCs at diagnosis are associated with good prognosis in DNMT3AmutNPM1mutAMLs
- Author
-
Donato, Elisa, Correia, Nadia, Andresen, Carolin, Karpova, Darja, Würth, Roberto, Klein, Corinna, Sohn, Markus, Przybylla, Adriana, Zeisberger, Petra, Rothfelder, Kathrin, Salih, Helmut, Bonig, Halvard, Stasik, Sebastian, Röllig, Christoph, Dolnik, Anna, Bullinger, Lars, Buchholz, Frank, rth, Christian, Hübschmann, Daniel, and Trumpp, Andreas
- Abstract
AML is a heterogeneous disease characterized by high rate of relapse and mortality. While chemotherapies may eradicate blasts, they are less effective in eliminating relapse-causing Leukemic Stem Cells (LSCs). Although LSCs are usually identified as CD34+CD38-cells, there is significant heterogeneity in surface marker expression and CD34-LSCs exist particularly in NPM1mutAMLs. By analyzing diagnostic primary DNMT3AmutNPM1mutAML samples, we suggest a novel flow cytometry sorting strategy particularly useful for CD34negAML subtypes. To enrich for LSCs independently of CD34 status, positive selection for GPR56 and negative selection for NKG2D-Ligands are employed. We demonstrate that the functional reconstitution capacity of CD34-and CD34+LSCs as well as their transcriptomes are very similar supporting phenotypic plasticity. Furthermore, we show that while CD34+subpopulations can contain next to LSCs also normal and/or pre-leukemic Hematopoietic Stem Cells (HSCs), this is not the case in CD34-GPR56+NKG2DL-enriched LSCs which thus can be isolated with high purity. Finally, we show that AML patients, who retain at time of diagnosis a reserve of normal and/or preleukemic HSCs in their bone marrow able to reconstitute immunocompromised mice, have significant longer relapse-free and overall survival compared to AML patients in whom functional HSCs are no longer detectable.
- Published
- 2022
- Full Text
- View/download PDF
229. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia
- Author
-
Jarisch, Andrea, Wiercinska, Eliza, Huenecke, Sabine, Bremm, Melanie, Cappel, Claudia, Hauler, Julian, Rettinger, Eva, Soerensen, Jan, Hellstern, Helen, Klusmann, Jan-Henning, Ciesek, Sandra, Bonig, Halvard, and Bader, Peter
- Abstract
•For patients after immune cell therapy, the risks of Coronavirus disease 19-associated complications are much higher than for the general population, supporting prioritization of vaccine access.•No previous studies have reported cellular immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients after anti-CD19 chimeric antigen receptor (CAR) T cell therapy.•SARS-CoV-2 mRNA vaccines induce robust and potentially clinically meaningful T cell responses to SARS-CoV-2 vaccines in patients with anti-CD19 CAR T cell therapy-mediated humoral immunodeficiency.•No severe vaccine-related grade 3 or 4 adverse events, graft-versus-host exacerbation, or relapse were observed in our cohort.
- Published
- 2022
- Full Text
- View/download PDF
230. Implication of ICOSLG on Relapse in Infant T(4;11) Acute Lymphoblastic Leukemia
- Author
-
Külp, Marius, Siemund, Anna Lena, Meyer, Claus, Larghero, Patrizia, Dietz, Alissa, Alten, Julia, Cario, Gunnar, Caye-Eude, Aurélie, Cavé, Hélène, Bardini, Michela, De Lorenzo, Paola, Cazzaniga, Giovanni, Diehl, Laura, Bonig, Halvard, and Marschalek, Rolf
- Abstract
Infant t(4;11) acute lymphoblastic leukemia (ALL) is associated with a high relapse rate with 4-year event-free survival (EFS) of only 36%. Relapse has been shown to be the major cause of death as 83% of relapsed infant t(4;11) ALL patients die within three years of diagnosis. Therefore, it is of utmost therapeutic interest to elucidate molecular mechanisms of relapse.
- Published
- 2021
- Full Text
- View/download PDF
231. Expression of HLA-DR by mesenchymal stromal cells in the platelet lysate era: an obsolete release criterion for MSCs?
- Author
-
Kuçi, Zyrafete, Piede, Natascha, Vogelsang, Kathrin, Pfeffermann, Lisa-Marie, Wehner, Sibylle, Salzmann-Manrique, Emilia, Stais, Miriam, Kreyenberg, Hermann, Bonig, Halvard, Bader, Peter, and Kuçi, Selim
- Subjects
- *
HLA-DR antigens , *STROMAL cells , *MONONUCLEAR leukocytes , *HISTOCOMPATIBILITY antigens , *INDOLEAMINE 2,3-dioxygenase , *BIOMARKERS - Abstract
Background: According to the definition of the International Society for Cell and Gene Therapy (ISCT), mesenchymal stromal cells (MSCs) do not express HLA-DR. This phenotypic marker as a release criterion for clinical use was established at a time when MSCs were expanded in fetal bovine serum (FBS)-containing media. Replacement of FBS with platelet lysate (PLs) as a medium supplement induced a significantly higher fraction of MSCs to express MHC class II antigens. Methods: As this raised concerns that such MSCs may play the role of antigen-presenting cells for T cells, in the current study, we studied major factors that may induce HLA-DR on MSCs by means of flow cytometry and real-time polymerase chain reaction. The immunomodulatory potential of MSCs was assessed by a mixed lymphocyte reaction. Results: Our results demonstrated that a very low percentage of generated and expanded MSCs in FBS express HLA-DR (median: 1.1%, range: 0.3–22%) compared to MSCs generated and expanded in PLs (median: 28.4%, range: 3.3–73.7%). Analysis of the cytokine composition of ten PLs showed a significant positive correlation between the levels of IL-1β, IL-4, IL-10, IL-17, bFGF and expression of HLA-DR, in contrast to no correlation with the age of MSC donors and HLA-DR (r = 0.21). Both MSCs expressing low and high levels of HLA-DR expressed class II transactivator (CIITA), a master gene coding for these molecules. Our results demonstrate for the first time that MSCs with constitutively high levels of HLA-DR also express moderate levels of indoleamine 2,3-dioxygenase (IDO). Treatment of MSCs with multiple doses of TGF-β1 at passage 0 (P0) and passage 1 (P1) completely abrogated HLA-DR and IDO expression. In contrast, treatment of MSCs with a single dose of TGF-β1 after P0 only partially reduced the expression of HLA-DR and CIITA. Remarkably, increased expression of HLA-DR on MSCs that constitutively express high levels of this antigen after overnight incubation with IFN-γ was rather unaffected by incubation with TGF-β1. However, treatment of MSCs with TGF-β1 for 24 h completely abrogated constitutive expression of IDO. Conclusions: Irrespective of HLA-DR expression at the population level, all MSC preparations significantly inhibited the proliferation of stimulated peripheral blood mononuclear cells, indicating that HLA-DR represents an obsolete release marker for the clinical use of MSCs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
232. Wnt/β-Catenin-Signaling Modulates Megakaryopoiesis at the Megakaryocyte-Erythrocyte Progenitor Stage in the Hematopoietic System.
- Author
-
Yalcin, Burak H., Macas, Jadranka, Wiercinska, Eliza, Harter, Patrick N., Fawaz, Malak, Schmachtel, Tessa, Ghiro, Ilaria, Bieniek, Ewa, Kosanovic, Djuro, Thom, Sonja, Fruttiger, Marcus, Taketo, Makoto M., Schermuly, Ralph T., Rieger, Michael A., Plate, Karl H., Bonig, Halvard, and Liebner, Stefan
- Subjects
- *
HEMATOPOIETIC system , *BLOOD cells , *RUNX proteins , *PLATELET-derived growth factor , *HEMATOPOIETIC stem cells , *WNT signal transduction , *ERYTHROCYTES , *BONE marrow - Abstract
The bone marrow (BM) hematopoietic system (HS) gives rise to blood cells originating from hematopoietic stem cells (HSCs), including megakaryocytes (MKs) and red blood cells (erythrocytes; RBCs). Many steps of the cell-fate decision remain to be elucidated, being important for cancer treatment. To explore the role of Wnt/β-catenin for MK and RBC differentiation, we activated β-catenin signaling in platelet-derived growth factor b (Pdgfb)-expressing cells of the HS using a Cre-lox approach (Ctnnb1BM-GOF). FACS analysis revealed that Pdgfb is mainly expressed by megakaryocytic progenitors (MKPs), MKs and platelets. Recombination resulted in a lethal phenotype in mutants (Ctnnb1BM-GOFwt/fl, Ctnnb1BM-GOFfl/fl) 3 weeks after tamoxifen injection, showing an increase in MKs in the BM and spleen, but no pronounced anemia despite reduced erythrocyte counts. BM transplantation (BMT) of Ctnnb1BM-GOF BM into lethally irradiated wildtype recipients (BMT-Ctnnb1BM-GOF) confirmed the megakaryocytic, but not the lethal phenotype. CFU-MK assays in vitro with BM cells of Ctnnb1BM-GOF mice supported MK skewing at the expense of erythroid colonies. Molecularly, the runt-related transcription factor 1 (RUNX1) mRNA, known to suppress erythropoiesis, was upregulated in Ctnnb1BM-GOF BM cells. In conclusion, β-catenin activation plays a key role in cell-fate decision favoring MK development at the expense of erythroid production. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
233. Automatic generation of alloreactivity-reduced donor lymphocytes and hematopoietic stem cells from the same mobilized apheresis product.
- Author
-
Wiercinska, E., Quade-Lyssy, P., Hümmer, C., Beifuß, J., Akarkach, K., Poppe, C., Olevska, V., Dzionek, J., Lahnor, H., Bosio, A., Papanikolaou, E., and Bonig, Halvard
- Subjects
- *
HEMATOPOIETIC stem cells , *HEMATOPOIETIC stem cell transplantation , *KILLER cells , *LYMPHOCYTES , *PROGENITOR cells - Abstract
Introduction: In vitro or in vivo depletion of alloreactive T cells can facilitate haplo-identical hematopoietic stem cell transplantation (HSCT). Very satisfactory transplant outcomes were thus reported for TCRαβ/CD19-depleted hematopoietic stem/progenitor cell (HSPC) grafts. The current semi-automatic manufacturing process on the CliniMACS Plus, although robust, still requires a significant amount of manual labor to be completed. Towards advancing and further facilitating large scale cell processing, a new TCRαβ/CD19 depletion module combined with the previously described CD45RA depletion module (to serve as allo-reactivity attenuated donor lymphocyte infusion) was established on the CliniMACS Prodigy. Methods: We evaluated six apheresis products from G-CSF-mobilized volunteer donors which were split automatically by the Prodigy, one portion each depleted of CD45RA+ or of TCRαβ+ and CD19+ cells. We investigated critical quality attributes for both products. Products were assessed for recovery of HSPCs and mature subsets, as well as depletion efficiency of targeted cells using flow cytometry. Effects of apheresis and product age post 48 h storage at 2–6 °C as well as freeze-thawing on product viability and recovery of WBC and HPSCs were assessed by flow cytometry. Results: Ten sequential automatic processes were completed with minimal hands-on time beyond tubing set installation. Depletion efficiency of CD45RA+ resp. TCRαβ+ and CD19+ cells was equivalent to previous reports, achieving mean depletions of 4 log of targeted cells for both products. HSPC products retained TCRγδ+ and NK cells. 48 h storage of apheresis product was associated with the expected modest loss of HSPCs, but depletions remained efficient. Depleted products were stable until at least 72 h after apheresis with stem cell viabilities > 90%. Freeze-thawing resulted in loss of NK cells; post-thaw recovery of viable CD45+ and HSPCs was > 70% and in line with expectation. Conclusion: The closed, GMP-compatible process generates two separate medicinal products from the same mobilized apheresis product. The CD45RA-depleted products contained functional memory T cells, whereas the TCRαβ/CD19-depleted products included HSPCs, TCRγδ+ and NK cells. Both products are predicted to be effectively depleted of GVH-reactivity while providing immunological surveillance, in support of haplo-identical HSCT. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
234. Simulating Space Conditions Evokes Different DNA Damage Responses in Immature and Mature Cells of the Human Hematopoietic System.
- Author
-
Handwerk, Leonie, Schreier, Heike Katrin, Kraft, Daniela, Shreder, Kateryna, Hemmersbach, Ruth, Hauslage, Jens, Bonig, Halvard, Wiesmüller, Lisa, Fournier, Claudia, and Rall-Scharpf, Melanie
- Subjects
- *
HEMATOPOIETIC system , *DOUBLE-strand DNA breaks , *ASTROPHYSICAL radiation , *CD45 antigen , *PROGENITOR cells , *REDUCED gravity environments , *SINGLE-stranded DNA , *DNA damage - Abstract
The impact of space radiation and microgravity on DNA damage responses has been discussed controversially, largely due to the variety of model systems engaged. Here, we performed side-by-side analyses of human hematopoietic stem/progenitor cells (HSPC) and peripheral blood lymphocytes (PBL) cultivated in a 2D clinostat to simulate microgravity before, during and after photon and particle irradiation. We demonstrate that simulated microgravity (SMG) accelerates the early phase of non-homologous end joining (NHEJ)-mediated repair of simple, X-ray-induced DNA double-strand breaks (DSBs) in PBL, while repair kinetics in HSPC remained unaltered. Repair acceleration was lost with increasing LET of ion exposures, which increases the complexity of DSBs, precluding NHEJ and requiring end resection for successful repair. Such cell-type specific effect of SMG on DSB repair was dependent on the NF-кB pathway pre-activated in PBL but not HSPC. Already under unperturbed growth conditions HSPC and PBL suffered from SMG-induced replication stress associated with accumulation of single-stranded DNA and DSBs, respectively. We conclude that in PBL, SMG-induced DSBs promote repair of radiation-induced damage in an adaptive-like response. HSPC feature SMG-induced single-stranded DNA and FANCD2 foci, i.e., markers of persistent replication stress and senescence that may contribute to a premature decline of the immune system in space. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
235. Corrigendum to "Characterization of Bone Marrow Mononuclear Cells on Biomaterials for Bone Tissue Engineering In Vitro".
- Author
-
Henrich, Dirk, Verboket, René, Schaible, Alexander, Kontradowitz, Kerstin, Oppermann, Elsie, Brune, Jan C., Nau, Christoph, Meier, Simon, Bonig, Halvard, Marzi, Ingo, and Seebach, Caroline
- Subjects
BONE marrow ,BIOMATERIALS - Abstract
[This corrects the article DOI: 10.1155/2015/762407.]. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
236. Response: More about multiple sclerosis, natalizumab, and CD34+hematopoietic progenitors
- Author
-
Bonig, Halvard, Wundes, Annette, and Papayannopoulou, Thalia
- Published
- 2008
- Full Text
- View/download PDF
237. Donor‐type red blood cell transfusion to deplete isoagglutinins prior to allogeneic stem cell transplantation from ABO major incompatible bone marrow donors.
- Author
-
Jarisch, Andrea, Salzmann‐Manrique, Emilia, Soerensen, Jan, Sach, Gudrun, Rettinger, Eva, Willasch, Andre, Bakhtiar, Shahrzad, Klarmann, Dieter, Bräuninger, Susanne, Moser, Laura, Fekadu, Julia, Hutter, Martin, Klingebiel, Thomas, Klusmann, Jan‐Henning, Bader, Peter, and Bonig, Halvard
- Subjects
- *
RED blood cell transfusion , *BLOOD group incompatibility , *STEM cell transplantation , *BONE marrow , *ERYTHROCYTES - Abstract
Summary: ABO incompatibility affects approximately 40% of allogeneic stem cell transplants in Caucasian patient populations. Because bone marrow (BM), the preferred graft from paediatric sibling donors and for non‐malignant diseases, has a red blood cell (RBC) content similar to blood, anti‐donor isoagglutinins must either be depleted from the recipient or RBCs removed from the graft. To achieve tolerability of unmanipulated BM grafts, we used controlled infusions of donor ABO‐type RBC units to deplete isoagglutinins before the transplant. This retrospective study evaluates the outcomes of 52 ABO major incompatible BM transplants performed at our centre between 2007 and 2019. The use of donor‐type RBC transfusions was well tolerated. They effectively reduced isoagglutinins levels, typically achieving target titres after one (60%) or two (29%) transfusions. The approach allowed for successful and uneventful infusions of unmanipulated BM which provided timely engraftment. The transplant outcomes were not inferior to those of a matched‐pair control group of patients with ABO‐identical donors. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
238. Validation of an ICH Q2 Compliant Flow Cytometry-Based Assay for the Assessment of the Inhibitory Potential of Mesenchymal Stromal Cells on T Cell Proliferation.
- Author
-
Piede, Natascha, Bremm, Melanie, Farken, Anne, Pfeffermann, Lisa-Marie, Cappel, Claudia, Bonig, Halvard, Fingerhut, Theres, Puth, Laura, Vogelsang, Kathrin, Peinelt, Andreas, Marschalek, Rolf, Müller, Matthias, Bader, Peter, Kuçi, Zyrafete, Kuçi, Selim, and Huenecke, Sabine
- Subjects
- *
MONONUCLEAR leukocytes , *T cells , *STROMAL cells , *CELL proliferation - Abstract
Mesenchymal stromal cells (MSCs) have the potential to suppress pathological activation of immune cells and have therefore been considered for the treatment of Graft-versus-Host-Disease. The clinical application of MSCs requires a process validation to ensure consistent quality. A flow cytometry-based mixed lymphocyte reaction (MLR) was developed to analyse the inhibitory effect of MSCs on T cell proliferation. Monoclonal antibodies were used to stimulate T cell expansion and determine the effect of MSCs after four days of co-culture based on proliferation tracking with the violet proliferation dye VPD450. Following the guidelines of the International Council for Harmonisation (ICH) Q2 (R1), the performance of n = 30 peripheral blood mononuclear cell (PBMC) donor pairs was assessed. The specific inhibition of T cells by viable MSCs was determined and precision values of <10% variation for repeatability and <15% for intermediate precision were found. Compared to a non-compendial reference method, a linear correlation of r = 0.9021 was shown. Serial dilution experiments demonstrated a linear range for PBMC:MSC ratios from 1:1 to 1:0.01. The assay was unaffected by PBMC inter-donor variability. In conclusion, the presented MLR can be used as part of quality control tests for the validation of MSCs as a clinical product. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
239. HIV-1 Infection of Long-Lived Hematopoietic Precursors In Vitro and In Vivo.
- Author
-
Renelt, Sebastian, Schult-Dietrich, Patrizia, Baldauf, Hanna-Mari, Stein, Stefan, Kann, Gerrit, Bickel, Markus, Kielland-Kaisen, Ulrikke, Bonig, Halvard, Marschalek, Rolf, Rieger, Michael A., Dietrich, Ursula, and Duerr, Ralf
- Subjects
- *
HIV , *HEMATOPOIETIC stem cells - Abstract
Latent reservoirs in human-immunodeficiency-virus-1 (HIV-1)-infected individuals represent a major obstacle in finding a cure for HIV-1. Hematopoietic stem and progenitor cells (HSPCs) have been described as potential HIV-1 targets, but their roles as HIV-1 reservoirs remain controversial. Here we provide additional evidence for the susceptibility of several distinct HSPC subpopulations to HIV-1 infection in vitro and in vivo. In vitro infection experiments of HSPCs were performed with different HIV-1 Env-pseudotyped lentiviral particles and with replication-competent HIV-1. Low-level infection/transduction of HSPCs, including hematopoietic stem cells (HSCs) and multipotent progenitors (MPP), was observed, preferentially via CXCR4, but also via CCR5-mediated entry. Multi-lineage colony formation in methylcellulose assays and repetitive replating of transduced cells provided functional proof of susceptibility of primitive HSPCs to HIV-1 infection. Further, the access to bone marrow samples from HIV-positive individuals facilitated the detection of HIV-1 gag cDNA copies in CD34+ cells from eight (out of eleven) individuals, with at least six of them infected with CCR5-tropic HIV-1 strains. In summary, our data confirm that primitive HSPC subpopulations are susceptible to CXCR4- and CCR5-mediated HIV-1 infection in vitro and in vivo, which qualifies these cells to contribute to the HIV-1 reservoir in patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
240. Absence of the CXCR4 antagonist EPI-X4 from pharmaceutical human serum albumin preparations.
- Author
-
Gilg, Andrea, Harms, Mirja, Olari, Lia-Raluca, Urbanowitz, Ann-Kathrin, Bonig, Halvard, and Münch, Jan
- Subjects
- *
CXCR4 receptors , *CATHEPSIN D , *CATHEPSINS , *PROTEOLYTIC enzymes , *DRUGS - Abstract
Background: Endogenous Peptide Inhibitor of CXCR4 (EPI-X4) is a natural antagonist of the CXC chemokine receptor 4 (CXCR4). EPI-X4 is a 16-mer peptide that is released from human serum albumin (HSA) by acidic aspartic proteases such as Cathepsin D and E. Since human serum albumin (HSA) is an important medicinal substance we asked whether different pharmaceutical HSA products contain EPI-X4 which could have been generated during manufacturing and whether HSA can serve as a substrate for cathepsins despite of the presence of stabilizers like caprylate. Methods: Eight pharmaceutical HSA preparations representing all currently used fractionation technologies were analyzed. The previously described specific EPI-X4 ELISA was used for quantification; in vitro EPI-X4 generation by acidification in the presence or absence of cathepsins was followed by quantification with ELISA. Results: None of the pharmaceutical HSA preparations tested contained EPI-X4. Acidification of HSA did not generate EPI-X4. Addition of cathepsins D and E to acidified HSA yielded high concentrations of EPI-X4 in all HSA preparations, indistinguishable between individual products. Conclusion: Medicinal HSA preparations per se do not contain EPI-X4, but will replenish its precursor which can be cleaved to EPI-X4 in vivo, environmental conditions permitting. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
241. Allogeneic transplant procurement in the times of COVID-19: Quality report from the central European cryopreservation site.
- Author
-
Wiercinska, Eliza, Schlipfenbacher, Vera, Bug, Gesine, Bader, Peter, Verbeek, Mareike, Seifried, Erhard, and Bonig, Halvard
- Subjects
- *
CRYOPRESERVATION of cells , *COVID-19 , *COVID-19 pandemic , *STEM cell transplantation , *STEM cells , *TRANSPLANTATION of organs, tissues, etc. - Abstract
Background: Because of limitations of transportation imposed by the COVID-19 pandemic, current recommendation calls for cryopreservation of allogeneic stem cell transplants before patient conditioning. A single cell therapy laboratory was selected to function as the central cryopreservation hub for all European registry donor transplants intended for the Australian-Pacific region. We examined properties of these transplants to ascertain how quality is maintained.Methods: We analyzed 100 pandemic-related allogeneic mobilized blood-derived stem cell apheresis products generated at 30 collection sites throughout Europe, shipped to and cryopreserved at our center between April and November of 2020. Products were shipped in the cool, subsequently frozen with DMSO as cryoprotectant. Irrespective of origin, all products were frozen within the prescribed shelf-life of 72 h.Results: Prior to cryopreservation, viable stem cell and leukocyte count according to the collection site and our reference laboratory were highly concordant (r2 = 0.96 and 0.93, respectively) and viability was > 90% in all instances. Median nominal post-thaw recovery of viable CD34+ cells was 42%. Weakly associated with poorer CD34+ cell recovery was higher leukocyte concentration, but not time lag between apheresis or addition of cryopreservant, respectively, and start of freezing. The correlation between pre- and post-thaw CD34+ cell dose was high (r2 = 0.85), hence predictable. Neutrophil and platelet engraftment were prompt with no evidence of dose dependency within the range of administered cell doses (1.31-15.56 × 106 CD34+ cells/kg).Conclusions: General cryopreservation of allogeneic stem cell transplants is feasible. While more than half of the CD34+ cell content is lost, the remaining stem cells ensure timely engraftment. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
242. Generation and validation of a formula to calculate hemoglobin loss on a cohort of healthy adults subjected to controlled blood loss.
- Author
-
Hahn-Klimroth, Max, Loick, Philipp, Kim-Wanner, Soo-Zin, Seifried, Erhard, and Bonig, Halvard
- Subjects
- *
HEMOGLOBINS , *FETAL hemoglobin , *SURGICAL blood loss , *SUPERVISED learning , *ERYTHROCYTES , *OPERATIVE surgery , *RESEARCH , *BLOOD transfusion , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies , *ANEMIA , *LONGITUDINAL method - Abstract
Background: The ability to approximate intra-operative hemoglobin loss with reasonable precision and linearity is prerequisite for determination of a relevant surgical outcome parameter: This information enables comparison of surgical procedures between different techniques, surgeons or hospitals, and supports anticipation of transfusion needs. Different formulas have been proposed, but none of them were validated for accuracy, precision and linearity against a cohort with precisely measured hemoglobin loss and, possibly for that reason, neither has established itself as gold standard. We sought to identify the minimal dataset needed to generate reasonably precise and accurate hemoglobin loss prediction tools and to derive and validate an estimation formula.Methods: Routinely available clinical and laboratory data from a cohort of 401 healthy individuals with controlled hemoglobin loss between 29 and 233 g were extracted from medical charts. Supervised learning algorithms were applied to identify a minimal data set and to generate and validate a formula for calculation of hemoglobin loss.Results: Of the classical supervised learning algorithms applied, the linear and Ridge regression models performed at least as well as the more complex models. Most straightforward to analyze and check for robustness, we proceeded with linear regression. Weight, height, sex and hemoglobin concentration before and on the morning after the intervention were sufficient to generate a formula for estimation of hemoglobin loss. The resulting model yields an outstanding R2 of 53.2% with similar precision throughout the entire range of volumes or donor sizes, thereby meaningfully outperforming previously proposed medical models.Conclusions: The resulting formula will allow objective benchmarking of surgical blood loss, enabling informed decision making as to the need for pre-operative type-and-cross only vs. reservation of packed red cell units, depending on a patient's anemia tolerance, and thus contributing to resource management. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
243. Donor-intrinsic variables determine mobilization efficiency: analyses from a cohort of sixty twice-mobilized stem cell donors.
- Author
-
Kim-Wanner, Soo-Zin, Lee, Seo-Youn, Seifried, Erhard, and Bonig, Halvard
- Subjects
- *
STEM cell donors , *STEM cell transplantation , *COHORT analysis , *STEM cells , *LEUKAPHERESIS , *RESEARCH , *GRANULOCYTE-colony stimulating factor , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *BIOTHERAPY , *COMPARATIVE studies , *HEMAPHERESIS , *HEMATOPOIETIC stem cell transplantation , *ANTIGENS - Abstract
Background: Healthy volunteer registry donors have become the backbone of stem cell transplantation programs. While most registrants will never become actual donors, a small minority are called upon twice, most commonly for the same patient because of poor graft function. Anecdotal evidence provides no hard reasons to disallow second-time mobilized apheresis, but few centers have treated enough two-time donors for definitive conclusions. Moreover, for reasons unknown, the efficiency of G-CSF varies greatly between donations.Methods: Comparison of outcomes of first vs. second donations can formally confirm G-CSF responsiveness as intrinsically, likely genetically, determined. In our database, we identified 60 donors (1.3%) who received two cycles of G-CSF 24 days to 4 years apart and systematically compared mobilization outcomes.Results: First and second mobilization and collection proceeded without severe or unusual adverse effects. First-time mobilization efficiency was highly predictive of second-time mobilization. Neither mobilization efficiency nor time lag between donations affected the similarity of first- and second-time mobilization outcomes.Conclusions: With the caveat that only donors with an unremarkable first donation were cleared for a second, our data indicate that a second donation is feasible, equally tolerable as a first donation, and efficient. Moreover, the data strongly support the notion of donor-intrinsic variables dictating mobilization response and argue against relevant damage to the stem cell compartment during mobilization with rhG-CSF. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
244. The transcription factor TAL1 and miR-17-92 create a regulatory loop in hematopoiesis.
- Author
-
Meyer, Annekarin, Herkt, Stefanie, Kunze-Schumacher, Heike, Kohrs, Nicole, Ringleb, Julia, Schneider, Lucas, Kuvardina, Olga N., Oellerich, Thomas, Häupl, Björn, Krueger, Andreas, Seifried, Erhard, Bonig, Halvard, and Lausen, Joern
- Subjects
- *
TRANSCRIPTION factors , *GENE regulatory networks , *MICRORNA , *CANCER invasiveness , *GENE expression - Abstract
A network of gene regulatory factors such as transcription factors and microRNAs establish and maintain gene expression patterns during hematopoiesis. In this network, transcription factors regulate each other and are involved in regulatory loops with microRNAs. The microRNA cluster miR-17-92 is located within the MIR17HG gene and encodes six mature microRNAs. It is important for hematopoietic differentiation and plays a central role in malignant disease. However, the transcription factors downstream of miR-17-92 are largely elusive and the transcriptional regulation of miR-17-92 is not fully understood. Here we show that miR-17-92 forms a regulatory loop with the transcription factor TAL1. The miR-17-92 cluster inhibits expression of TAL1 and indirectly leads to decreased stability of the TAL1 transcriptional complex. We found that TAL1 and its heterodimerization partner E47 regulate miR-17-92 transcriptionally. Furthermore, miR-17-92 negatively influences erythroid differentiation, a process that depends on gene activation by the TAL1 complex. Our data give example of how transcription factor activity is fine-tuned during normal hematopoiesis. We postulate that disturbance of the regulatory loop between TAL1 and the miR-17-92 cluster could be an important step in cancer development and progression. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
245. Modest and nonessential roles of the endocannabinoid system in immature hematopoiesis of mice.
- Author
-
Danner, Eva, Hoffmann, Frauke, Lee, Seo-Youn, Cordes, Fabian, Orban, Sabine, Dauber, Katrin, Chudziak, Doreen, Spohn, Gabriele, Wiercinska, Eliza, Tast, Benjamin, Karpova, Darja, and Bonig, Halvard
- Subjects
- *
HEMATOPOIESIS , *BONE marrow cells , *G protein coupled receptors , *HEMATOPOIETIC stem cells , *BLOOD cells - Abstract
• CB2 is expressed on hematopoietic cells, including stem cells. • Several CB2 targeting compounds lack specificity. • Loss of CB2 receptor results in mild lymphocytosis in mice. • Endocannabinoid signaling through CB2 has no major effects on immature hematopoiesis during homeostasis or hematopoietic stress. Endocannabinoids are lipid mediators that signal via several seven-transmembrane domain G protein-coupled receptors. The endocannabinoid receptor CB2 is expressed on blood cells, including stem cells, and mediates the effects of cannabinoids on the immune system. The role of the endocannabinoid system in immature hematopoiesis is largely elusive. Both direct effects of endocannabinoids on stem cells and indirect effects through endocannabinoid-responsive niche cells like macrophages have been reported. Using two different CB2-deficient mouse models, we studied the role of the endocannabinoid system in immature hematopoiesis. Moreover, we utilized both models to assess the specificity of putative CB2 agonists. As heterodimerization of CB2 and CXCR4, which is highly expressed on hematopoietic stem cells, has already been described, we also assessed potential consequences of CB2 loss for CXCR4/CXCL12 signaling. Overall, no differential effects were observed with any of the compounds tested; the compounds barely induced signaling by themselves, whereas they attenuated CXCL12-induced signals in both CB2-competent and CB2-deficient cells. In vivo experiments were therefore by necessity restricted to loss-of-function studies in knockout (CB2–/–) mice: Except for mild lymphocytosis and slightly elevated circulating progenitor cells, homeostatic hematopoiesis in CB2–/– mice appears to be entirely normal. Mobilization in response to pharmacological stimuli, Plerixafor or G-CSF, was equally potent in wild-type and CB2–/– mice. CB2–/– bone marrow cells reconstituted hematopoiesis in lethally irradiated recipients with engraftment kinetics indistinguishable from those of wild-type grafts. In summary, we found the endocannabinoid system to be largely dispensable for normal murine hematopoiesis. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
246. Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte Infusions.
- Author
-
Merker, Michael, Salzmann-Manrique, Emilia, Katzki, Verena, Huenecke, Sabine, Bremm, Melanie, Bakhtiar, Shahrzad, Willasch, Andre, Jarisch, Andrea, Soerensen, Jan, Schulz, Ansgar, Meisel, Roland, Bug, Gesine, Bonig, Halvard, Klingebiel, Thomas, Bader, Peter, and Rettinger, Eva
- Subjects
- *
RITUXIMAB , *KILLER cells , *HEMATOLOGIC malignancies , *MOLECULAR pathology , *HEMATOPOIETIC stem cell transplantation , *CELLULAR therapy , *LYMPHOCYTES - Abstract
• Compared with donor lymphocyte infusion (DLI), T cell dose was significantly increased with cytokine-induced killer (CIK) cell therapy. • T cell recovery was significantly improved after CIK cell therapy (P <.0001). • CIK cells are endowed with a reduced propensity to cause GVHD. • Compared with DLI, CIK cell therapy showed a significantly reduced 6-month calculated cumulative incidence of relapse. • CIK cell therapy may be a promising alternative to classic DLI when leukemia burden is low. Well-established donor lymphocyte infusion (DLI) and novel cytokine-induced killer (CIK) cell therapy for the treatment of relapsing hematologic malignancies after allogeneic hematopoietic stem cell transplantation (HSCT) were compared with respect to feasibility, safety, and efficacy. Altogether, a total of 221 infusions were given to 91 patients (DLI, n = 55; CIK, n = 36). T cell recovery was significantly improved after CIK cell therapy (P <.0001). Although patients with CIK cell treatment showed a significantly worse prognosis at the time of HSCT (risk score, 1.7 versus 2.1; P <.0001), DLI and CIK cell therapy induced complete remission (CR) in 29% and 53% patients, respectively, whereas relapse occurred in 71% and 47%. In both groups, all patients with overt hematologic relapse at the time of immunotherapy (DLI, n = 11; CIK, n = 8) succumbed to their disease, while 36% and 68% patients with DLI or CIK cell therapy applied due to molecular relapse or active disease at the time of transplantation achieved CR. The 6-month overall survival rate in the latter patients was 57% and 77%, respectively, with a median follow-up of 27.9 months (range,.9 to 149.2 months). The 6-month cumulative incidence of relapse was 55% and 22% in patients who received DLI and CIK cell therapy, respectively (P =.012). Acute graft-versus-host disease developed in 35% of the patients who received DLI and in 25% of those who received CIK. No transfusion-related deaths occurred. These data, while underscoring the therapeutic value of conventional DLI, suggest the improved safety and to a certain extent efficacy of CIK cell therapy for patients at high risk for post-transplantation relapse of various hematologic malignancies. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
247. Epstein-Barr virus–specific cytokine-induced killer cells for treatment of Epstein-Barr virus–related malignant lymphoma.
- Author
-
Pfeffermann, Lisa-Marie, Pfirrmann, Verena, Huenecke, Sabine, Bremm, Melanie, Bonig, Halvard, Kvasnicka, Hans-Michael, Klingebiel, Thomas, Bader, Peter, and Rettinger, Eva
- Subjects
- *
TREATMENT of Epstein-Barr virus diseases , *KILLER cells , *CYTOKINES , *LYMPHOMAS , *CYTOTOXIC T cells - Abstract
Background Prolonged immunosuppression or delayed T-cell recovery may favor Epstein-Barr virus (EBV) infection or reactivation after allogeneic hematopoietic stem cell transplantation (HSCT), which can lead to post-transplant lymphoproliferative disease (PTLD) and high-grade malignant B-cell lymphoma. Cytokine-induced killer (CIK) cells with dual specific anti-tumor and virus-specific cellular immunity may be applied in this context. Methods CIK cells with EBV-specificity were generated from peripheral blood mononuclear cells (PBMCs), expanded in the presence of interferon-γ, anti-CD3, interleukin (IL)-2 and IL-15 and were pulsed twice with EBV consensus peptide pool. CIK cells with EBV-specificity and conventional CIK cells were phenotypically and functionally analyzed. Additionally, CIK cells with EBV-specificity were applied to a patient with EBV-related PTLD rapidly progressing to highly aggressive B-cell lymphoma on a compassionate use basis after approval and agreement by the regulatory authorities. Results Pre-clinical analysis showed that generation of CIK cells with EBV-specificity was feasible. In vitro cytotoxicity analyses showed increased lysis of EBV-positive target cells, enhanced proliferative capacity and increased secretion of cytolytic and proinflammatory cytokines in the presence of EBV peptide-displaying target cells. In addition, 1 week after infusion of CIK cells with EBV-specificity, the patient's highly aggressive B-cell lymphoma persistently disappeared. CIK cells with EBV-specificity remained detectable for up to 32 days after infusion and infusion did not result in acute toxicity. Discussion The transfer of both anti-cancer potential and T-cell memory against EBV infection provided by EBV peptide-induced CIK cells might be considered a therapy for EBV-related PTLD. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
248. Generation of alloreactivity-reduced donor lymphocyte products retaining memory function by fully automatic depletion of CD45RA-positive cells.
- Author
-
Müller, Nina, Landwehr, Katharina, Langeveld, Kirsten, Stenzel, Joanna, Pouwels, Walter, van der Hoorn, Menno A.W.G., Seifried, Erhard, and Bonig, Halvard
- Subjects
- *
T cells , *STEM cell transplantation , *MAJOR histocompatibility complex , *GRAFT versus host disease , *IMMUNOLOGIC memory - Abstract
Background aims For patients needing allogeneic stem cell transplantation but lacking a major histocompatibility complex (MHC)-matched donor, haplo-identical (family) donors may be an alternative. Stringent T-cell depletion required in these cases to avoid lethal graft-versus-host disease (GVHD) can delay immune reconstitution, thus impairing defense against virus reactivation and attenuating graft-versus-leukemia (GVL) activity. Several groups reported that GVHD is caused by cells residing within the naive (CD45RA + ) T-cell compartment and proposed use of CD45RA-depleted donor lymphocyte infusion (DLI) to accelerate immune reconstitution. We developed and tested the performance of a CD45RA depletion module for the automatic cell-processing device CliniMACS Prodigy and investigated quality attributes of the generated products. Methods Unstimulated apheresis products from random volunteer donors were depleted of CD45RA + cells on CliniMACS Prodigy, using Good Manufacturing Practice (GMP)-compliant reagents and methods throughout. Using phenotypic and functional in vitro assays, we assessed the cellular constitution of CD45RA-depleted products, including T-cell subset analyses, immunological memory function and allo-reactivity. Results Selections were technically uneventful and proceeded automatically with minimal hands-on time beyond tubing set installation. Products were near-qualitatively CD45RA + depleted, that is, largely devoid of CD45RA + T cells but also of almost all B and natural killer cells. Naive and effector as well as γ/δ T cells were greatly reduced. The CD4:CD8 ratio was fivefold increased. Mixed lymphocyte reaction assays of the product against third-party leukocytes revealed reduced allo-reactivity compared to starting material. Anti-pathogen responses were retained. Discussion The novel, closed, fully GMP-compatible process on Prodigy generates highly CD45RA-depleted cellular products predicted to be clinically meaningfully depleted of GvH reactivity. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
249. Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B.
- Author
-
Miesbach, Wolfgang, Meijer, Karina, Coppens, Michiel, Kampmann, Peter, Klamroth, Robert, Schutgens, Roger, Tangelder, Marco, Castaman, Giancarlo, Schwäble, Joachim, Bonig, Halvard, Seifried, Erhard, Cattaneo, Federica, Meyer, Christian, and Leebeek, Frank W. G.
- Subjects
- *
GENE therapy , *HEMOPHILIA , *PROMOTERS (Genetics) , *GENE expression , *HEMORRHAGE - Abstract
Gene therapy for hemophilia B aims to ameliorate bleeding risk and provide endogenous factor IX (FIX) activity/synthesis through a single treatment, eliminating the requirement for FIX concentrate. AMT-060 combines an adeno-associated virus-5 (AAV5) vector with a liver-specific promoter driving expression of a codon-optimized wild-type human FIX gene. This multinational, open-label study included 10 adults with hemophilia B (FIX ≤ 2% of normal) and severe-bleeding phenotype. No participants tested positive for AAV5-neutralizing antibodies using a green-fluorescent protein-based assay, and all 10 were enrolled. A single dose of 5 x 1012or 2 x 1013 genome copies of AMT-060/kilogram was administered to 5 participants each. In the low-dose cohort, mean endogenous FIX activity increased to 4.4 IU/dL. Annualized FIX use was reduced by 81%, and mean annualized spontaneous bleeding rate (ASBR) decreased from 9.8% to 4.6% (53%). In the higher-dose cohort, mean FIX activity increased to 6.9 IU/dL. Annualized FIX use decreased by 73%, and mean ASBR declined from 3.0 to 0.9 (70%). There was no reduction in traumatic bleeds. FIX activity was stable in both cohorts, and 8 of 9 participants receiving FIX at study entry stopped prophylaxis. Limited, asymptomatic, and transient alanine aminotransferase elevations in the low-dose (n 5 1) and higher-dose (n 5 2) cohorts were treated with prednisolone. No decrease in FIX activity or capsid-specific T-cell responses were detected during transaminase elevations. A single infusion of AMT-060 had a positive safety profile and resulted in stable and clinically important increases in FIX activity, a marked reduction in spontaneous bleeds and FIX concentrate use, without detectable cellular immune responses against capsids. This trial was registered at www.clinicaltrials.gov as #NCT02396342; EudraCT #2013-005579-42. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
250. HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling.
- Author
-
Walter, Roland, Kuan-Ting Pan, Doebele, Carmen, Comoglio, Federico, Tomska, Katarzyna, Bohnenberger, Hanibal, Young, Ryan M., Jacobs, Laura, Keller, Ulrich, Bonig, Halvard, Engelke, Michael, Rosenwald, Andreas, Urlaub, Henning, Staudt, Louis M., Serve, Hubert, Zenz, Thorsten, and Oellerich, Thomas
- Subjects
- *
BURKITT'S lymphoma , *B cell receptors , *CANCER chemotherapy , *HEAT shock proteins , *APOPTOSIS , *THERAPEUTICS - Abstract
Burkitt lymphoma (BL) is an aggressive B-cell neoplasm that is currently treated by intensive chemotherapy in combination with anti-CD20 antibodies. Because of their toxicity, current treatment regimens are often not suitable for elderly patients or for patients in developing countries where BL is endemic. Targeted therapies for BL are therefore needed. In this study, we performed a compound screen in 17 BL cell lines to identify small molecule inhibitors affecting cell survival. We found that inhibitors of heat shock protein 90 (HSP90) induced apoptosis in BL cells in vitro at concentrations that did not affect normal B cells. By global proteomic and phosphoproteomic profiling, we show that, in BL, HSP90 inhibition compromises the activity of the pivotal B-cell antigen receptor (BCR)-proximal effector spleen tyrosine kinase (SYK), which we identified as an HSP90 client protein. Consistently, expression of constitutively active TEL-SYK counteracted the apoptotic effect of HSP90 inhibition. Together, our results demonstrate that HSP90 inhibition impairs BL cell survival by interfering with tonic BCR signaling, thus providing a molecular rationale for the use of HSP90 inhibitors in the treatment of BL. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.